Robin,
My connection to Amylin is that I drive by it every so often. It appears to me to be a one-trick pony-- but if that one trick is really good, the pony is going to do OK. I don't think Amylin has THE answer to NIDDM. The PPAR and RXR compounds are likely to do better. Which actually is what caught my eye about Biotech Holdings.
Just about any drug (caveat: by US or European or Japanese firms) with any literature behind it can be searched by its tradename. For example, a search on minoxidil or proscar will find the appropriate molecules. This is not limited to marketed drugs, just about any molecule that has been desribed in the literature (patent included) and named somewhere. I do not have much experience getting information about Chinese firms. I have calls in to various diabetes organizations in the US and they have never heard of Biotech Holdings or Diab II. That's what raised my suspicions. That DOES NOT mean it doesn't exist, obviously, just that it is tough to find. I would hope that the company would be a little more forthcoming with this info-- like, for example, when were the patents filed and in what countries? All the company has to do to send the stock through the roof is verify that the molecule exists (a paper, a patent, anything).
Good luck. I hope this is real, but until I can prove it to myself, I think I'll stay away. I count myself among those willing to pay a higher price for a little comfort.
Sunny and 70 today. Cheers.
|
